Literature DB >> 10914784

Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease.

M Siciliano1, E De Candia, S Ballarin, F M Vecchio, S Servidei, R Annese, R Landolfi, L Rossi.   

Abstract

Type III glycogen storage disease (GSD III) is an autosomal recessive disorder characterized by the accumulation of abnormal glycogen in the liver and, in most patients, in the muscle. Although liver fibrosis is a well-known consequence of GSD III, until now only eight cases of liver cirrhosis and two cases of hepatocellular carcinoma have been described in patients affected by this disease. In this case report, the authors describe the clinical history of a patient affected by GSD III who developed severe liver disease during her adult life, progressing from fibrosis to cirrhosis and finally to hepatocellular carcinoma. Until now, the hepatic involvement in GSD III has been considered by most authors as mild and almost always self-limiting. This report, together with the previously published cases, clearly indicates that severe and progressive liver disease may complicate this metabolic disorder. These observations advise a careful hepatologic follow-up of patients affected by GSD III.

Entities:  

Mesh:

Year:  2000        PMID: 10914784     DOI: 10.1097/00004836-200007000-00020

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  10 in total

1.  Glycogen storage disease type III in Inuit children.

Authors:  Paul James A Zimakas; Celia J Rodd
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

Review 2.  Targeting glycogen metabolism in bladder cancer.

Authors:  Carolyn Ritterson Lew; Sunny Guin; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2015-05-26       Impact factor: 14.432

Review 3.  Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?

Authors:  Erin Demo; Donald Frush; Marcia Gottfried; John Koepke; Anne Boney; Deeksha Bali; Y T Chen; Priya S Kishnani
Journal:  J Hepatol       Date:  2006-11-09       Impact factor: 25.083

Review 4.  Preclinical Development of New Therapy for Glycogen Storage Diseases.

Authors:  Baodong Sun; Elizabeth D Brooks; Dwight D Koeberl
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 5.  Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism.

Authors:  Ayelet Erez; Oleg A Shchelochkov; Sharon E Plon; Fernando Scaglia; Brendan Lee
Journal:  Am J Hum Genet       Date:  2011-04-08       Impact factor: 11.025

6.  Natural Progression of Canine Glycogen Storage Disease Type IIIa.

Authors:  Elizabeth D Brooks; Haiqing Yi; Stephanie L Austin; Beth L Thurberg; Sarah P Young; John C Fyfe; Priya S Kishnani; Baodong Sun
Journal:  Comp Med       Date:  2016-02       Impact factor: 0.982

Review 7.  Liver transplantation for malignancy: current treatment strategies and future perspectives.

Authors:  Christina Hackl; Hans J Schlitt; Gabriele I Kirchner; Birgit Knoppke; Martin Loss
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

8.  Characterization of a canine model of glycogen storage disease type IIIa.

Authors:  Haiqing Yi; Beth L Thurberg; Sarah Curtis; Stephanie Austin; John Fyfe; Dwight D Koeberl; Priya S Kishnani; Baodong Sun
Journal:  Dis Model Mech       Date:  2012-06-26       Impact factor: 5.758

9.  Diurnal variability of glucose tetrasaccharide (Glc4) excretion in patients with glycogen storage disease type III.

Authors:  Sarah P Young; Aleena Khan; Ela Stefanescu; Andrea M Seifts; Ghada Hijazi; Stephanie Austin; Priya S Kishnani
Journal:  JIMD Rep       Date:  2020-11-03

10.  Glucose-free/high-protein diet improves hepatomegaly and exercise intolerance in glycogen storage disease type III mice.

Authors:  Serena Pagliarani; Sabrina Lucchiari; Gianna Ulzi; Michela Ripolone; Raffaella Violano; Francesco Fortunato; Andreina Bordoni; Stefania Corti; Maurizio Moggio; Nereo Bresolin; Giacomo P Comi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-01       Impact factor: 5.187

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.